-+ 0.00%
-+ 0.00%
-+ 0.00%

Pliant Therapeutics Announces PLN-101095 Cancer Study Presentations at SITC 2026

PUBT·10/29/2026 20:59:20
Pliant Therapeutics Announces PLN-101095 Cancer Study Presentations at SITC 2026
  • Pliant Therapeutics will present PLN-101095 research at the Society for Immunotherapy of Cancer meeting in Phoenix on November 6-7, 2026.
  • Research indicates selective integrin targeting improves checkpoint inhibitor anti-tumor responses; plasma biomarkers predict sensitization in patients receiving PLN-101095.
  • The oral drug is enrolling patients in the Phase 1b portion of FORTIFY for advanced solid tumors resistant to checkpoint inhibitors.
  • FORTIFY evaluates PLN-101095 with pembrolizumab for safety, tolerability, pharmacokinetics and preliminary anti-tumor activity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291605PRIMZONEFULLFEED9856372) on October 29, 2026, and is solely responsible for the information contained therein.